Signet Investment Advisory Group Inc. lowered its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 5.3% in the first quarter, Holdings Channel.com reports. The firm owned 22,752 shares of the company’s stock after selling 1,273 shares during the quarter. Johnson & Johnson makes up about 2.4% of Signet Investment Advisory Group Inc.’s holdings, making the stock its 11th largest position. Signet Investment Advisory Group Inc.’s holdings in Johnson & Johnson were worth $3,527,000 as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in JNJ. GW&K Investment Management LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at about $35,000. Dark Forest Capital Management LP increased its stake in shares of Johnson & Johnson by 1,044.4% during the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after purchasing an additional 188 shares in the last quarter. Ruedi Wealth Management Inc. purchased a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $42,000. Kepos Capital LP purchased a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $45,000. Finally, FWL Investment Management LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $114,000. Institutional investors and hedge funds own 67.57% of the company’s stock.
Insider Activity at Johnson & Johnson
In related news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,163 shares of company stock worth $7,928,856. 0.20% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on JNJ
Johnson & Johnson Stock Down 0.8 %
Shares of JNJ opened at $166.01 on Wednesday. The firm has a market cap of $431.45 billion, a PE ratio of 33.61, a price-to-earnings-growth ratio of 2.89 and a beta of 0.54. The company’s fifty day moving average is $166.56 and its two-hundred day moving average is $161.43. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $181.04. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The company had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. Johnson & Johnson’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter last year, the business earned $2.59 EPS. Analysts forecast that Johnson & Johnson will post 10.75 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be issued a dividend of $1.19 per share. The ex-dividend date is Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.87%. Johnson & Johnson’s payout ratio is 96.36%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Trading Stocks: RSI and Why it’s Useful
- 5 Best Fintech Banks to Invest in Now
- Most Volatile Stocks, What Investors Need to Know
- 3 Smart AI ETFs For Intelligent Passive Investing Needs
- The Significance of Brokerage Rankings in Stock Selection
- 4 Reasons Zoom Video is Ready to Rock Into a Reversal
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
